Gastric cancer is one of the most common cancers worldwilde. The five-year survival for stage IV gastric cancer is around 5–10% in Western countries. Advanced gastric cancer is sensitive to numerous agents, but there is no generally accepted standard regimen. Here we report on a case of advanced gastric cancer occurring in a 72-year-old man who underwent treatment with capecitabine plus oxaliplatin, achieving a complete response. Free full text available at www.tumorionline.it
SuganoK.: Gastric cancer: pathogenesis, screening and treatment.Gastrointest Endosc Clin N Am, 18: 513–522, 2008.
3.
FoukakisT., LundellL., GubanskiM., LindP.A.: Advances in the treatment of patients with gastric adenocarcinoma.Acta Oncol, 46: 277–285, 2007.
4.
PistersP.W.T., KelsenD.P., TepperJ.E.: Cancer of the stomach. In: Cancer: principles and practice of oncology, 8th ed, DeVitaV.T.Jr., HellmanS., RosenbergS.A. (Eds), pp 1043–1079, Wolters Kluwer Health and Lippincott Williams & Wilkins, Philadelphia, PA, 2008.
5.
KangY.K., KangW.K., ShinD.B., ChenJ., XiongJ., WangJ., LichinitserM., GuanZ., KhasanovR., ZhengL., Philco-SalasM., SuarezT., SantamariaJ., ForsterG., McCloudP.I.: Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized phase III noninferiority trial.Ann Oncol, 20: 666–673, 2009.
6.
Barros-SilvaJ.D., LeitãoD., AlfonsoL., VieiraJ., Dinis-RibeiroM., FragosoM., BentoM.J., SantosL., FerreiraP., RegoS., BrandaoC., CarneiroF., LopesC., SchmittF., TexeiraM.R.: Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients.Br J Cancer, 100: 487–493, 2009.
7.
ZhangX.L., YangY.S., XuD.P., QuJ.H., GuoM.Z., GongY., HuangJ.: Comparative study on overexpression of HER2/neu and HER3 in gastric cancer.World J Surg, 33: 2112–2118, 2009.
8.
TannerM., HollmenM., JuntillaT.T., KapanenA.I., TommolaS., SoiniY., HelinH., SaloJ., JoensuuH., SihvoE., EleniusK., IsolaJ.: Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.Ann Oncol, 16: 273–278, 2005.
9.
CunninghamD., AllumW.H., StenningS.P., ThompsonJ.N., Van de VeldeC.J., NicolsonM., ScarfeJ.H., LoftsF.J., FalkS.J., IvesonT.J., SmithD.B., LangleyR.E., VermaM., WeedenS., ChuaY.J., MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.N Engl J Med, 355: 11–20, 2006.
10.
MacdonaldJ.S., SmalleyS.R., BenedettiJ., HundahlS.A., EstesN.C., StemmermannG.N., HallerD.G., AjaniJ.A., GundersonL.L., JessupJ.M., MartensonJ.A.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.N Engl J Med, 345: 725–730, 2001.
11.
MuradA.M., SantiagoF.F., PetroianuA., RochaP.R., RodriguesM.A., RauschM.: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.Cancer, 72: 37–41, 1993.
12.
PyrhonenS., KuitunenT., NyandotoP., KouriM.: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate plus supportive care with supportive care alone in patients with non-resectable gastric cancer.Br J Cancer, 71: 587–591, 1995.
13.
GlimeliusB., EkstromK., HoffmanK., GrafW., SjodenP.O., HaglundU., SvenssonC., EnanderL.K., LinnèT., SellstromH., HeumanR.: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.Ann Oncol, 8: 163–168, 1997.
14.
JanungerK.G., HafströmL., GlimeliusB.: Chemotherapy in gastric cancer: a review and update meta-analysis.Eur J Surg, 168: 597–608, 2002.
15.
WagnerA.D., GrotheW., HaertingJ., KleberG., GrotheyA., FleigW.E.: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.J Clin Oncol, 24: 2903–2909, 2006.
16.
CervantesA., RosellóS., RodaD., Rodríguez-BraunE.: The treatment of advanced gastric cancer: current strategies and future perspectives.Ann Oncol, 19(Suppl 5): 103–107, 2008.
17.
RossP., NicolsonM., CunninghamD., ValleJ., SeymourM., HarperP., PriceT., AndersonH., IvesonT., HickishT., LoftsF., NormanA.: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin and PVI 5-FU in advanced esophagogastric cancer.J Clin Oncol, 20: 1996–2004, 2002.
18.
CunninghamD., StarlingN., RaoS., IvesonT., NicolsonM., CoxonF., MiddletonG., DanielF., OatesJ., NormanA.R.; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom: Capecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med, 358: 36–46, 2008.
19.
BajettaE., VerzoniE., FerrarioE., DottiK., GevorgyanA., CelioL.: Fleasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer.Tumori, 95: 43–47, 2009.
20.
ArkenauH.T.: Gastric cancer in the era of molecularly targeted agents: current drug development strategies.J Cancer Res Clin Oncol, 135: 855–856, 2009.
KimM.A., JungE.J., LeeH.S., LeeH.E., JeonY.K., YangH.K., KimW.H.: Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction.Hum Pathol, 38: 1386–1393, 2007.
23.
YanoT., DoiT., OhtsuA., BokuN., HashizumeK., NakanishiM., OchiaiA.: Comparison of HER-2 gene amplification assessed by fluorescence in situ hybridization and HER-2 protein expression assessed by immunohistochemistry in gastric cancer.Oncol Rep, 15: 65–71, 2006.
24.
YuG.Z., ChenY., WangJ.J.: Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance.J Cancer Res Clin Oncol, 135: 1331–1339, 2009.
25.
BangY., ChungH., XuJ., LordickF., SawakiA., Al-SakaffN., LipatovO., SeeC., RueschoffJ., Van CutsemE.: Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial.J Clin Oncol, 27(Suppl 15): abstract 4556, 2009.
26.
Van CutsemE., KangY., ChungH., ShenL., SawakiA., LordickF., HillJ., LehleM., FeyereislovaA., BangY.: Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first line HER-2-positive advanced gastric cancer.J Clin Oncol, 27(Suppl 15): abstract LBA4509, 2009.
